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Low dose radiation risks for women




Background: Analyses of cancer mortality and incidence in Japanese A-bomb survivors have been used to estimate
radiation risks, which are generally higher for women. Relative Risk (RR) is usually modelled as a linear function of dose.
Extrapolation from data including high doses predicts small risks at low doses. Generalized Additive Models (GAMs)
are flexible methods for modelling non-linear behaviour.
Methods: GAMs are applied to cancer incidence in female low dose subcohorts, using anonymous public data for
the 1958 – 1998 Life Span Study, to test for linearity, explore interactions, adjust for the skewed dose distribution,
examine significance below 100 mGy, and estimate risks at 10 mGy.
Results: For all solid cancer incidence, RR estimated from 0 – 100 mGy and 0 – 20 mGy subcohorts is significantly
raised. The response tapers above 150 mGy. At low doses, RR increases with age-at-exposure and decreases with
time-since-exposure, the preferred covariate. Using the empirical cumulative distribution of dose improves model fit,
and capacity to detect non-linear responses. RR is elevated over wide ranges of covariate values. Results are stable
under simulation, or when removing exceptional data cells, or adjusting neutron RBE. Estimates of Excess RR at
10 mGy using the cumulative dose distribution are 10 – 45 times higher than extrapolations from a linear model fitted
to the full cohort. Below 100 mGy, quasipoisson models find significant effects for all solid, squamous, uterus, corpus,
and thyroid cancers, and for respiratory cancers when age-at-exposure > 35 yrs. Results for the thyroid are compatible
with studies of children treated for tinea capitis, and Chernobyl survivors. Results for the uterus are compatible with
studies of UK nuclear workers and the Techa River cohort.
Conclusion: Non-linear models find large, significant cancer risks for Japanese women exposed to low dose radiation
from the atomic bombings. The risks should be reflected in protection standards.
Keywords: Low dose radiation, Cancer, Women, Thyroid, Uterus, A-bomb, GAM
Background
Analyses of cancer mortality and incidence in Japanese A-
bomb survivors continue to play a key role in establishing
radiation risk estimates. The 1958–1998 incidence cohort
was analysed by Preston and co-workers [1], whose main
model assumes a linear dose response. Their study found
some evidence of radiation risk at doses below 150 mGy,
and higher risks for women. Previously Pierce and Pre-
ston [2] found a significant dose response for all solid
cancer incidence in the 0 – 100 mGy range. However,
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according to the EPA Blue Book [3] “it has not been
possible to demonstrate and quantify risk in the Lifes-
pan Study (of A-bomb survivors) at doses below about
100 mGy”. The ICRP [4] recommended annual dose limit
for occupational exposures is 20 mSv (whole body dose).
Some cancer studies find non-linear responses to radi-
ation [5–8] and there are some significant results at low
doses [9–16]. Low dose radiation risk was reviewed in
2003 [17] and remains a focus of research [18].
I consider cancer incidence in female Japanese A-bomb
survivors in the dose ranges 0 – 500 mGy, 0 – 100 mGy,
and 0 – 20 mGy, using the grouped anonymous (public)
incidence data for the 1958 – 1998 cohort.
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Attained age is the single most powerful predic-
tor of cancer incidence. Models can be refined using
birth cohort, age-at-exposure or time-since-exposure,
city, urban/rural residence, and dose. The Not In City
(NIC) group of Hiroshima and Nagasaki residents who
were out of the area at the time of bombing can be
included.
The analysis uses the Generalized Additive Model [19]
implemented in R [20] through the programme mgcv
[21]. GAM is a flexible technique for fitting non-linear
responses and covariate interactions. Models are investi-
gated for all solid cancers, and then applied to the most
common anatomical or histological groups and specific
sites within the female incidence data: digestive, genital,
respiratory, adenocarcinoma, other epithelial, squamous,
stomach, colon, liver, pancreas, gallbladder, rectum, uter-
ine, cervical, uterine corpus, ovarian, lung, breast, thyroid,
and central nervous system.
The analysis aims to test for linearity of the dose
response, explore the interaction of dose with attained
age, age-at-exposure and time-since-exposure, adjust for
the highly skewed distribution of dose, test whether the
response is significant below 100 mGy, and estimate the
risks at 10 mGy.
Methods
The public dataset LSSinc07 [22] was downloaded from
the Radiation Effects Research Foundation (RERF) [23].
Records with unknown dose were excluded, leaving
25,570 cells with grouped data on 17,448 solid cancers
among 105,427 survivors with 2,764,735 person-years of
follow-up. The covariate py denotes person-years obser-
vation in each cell. logage is the log of age, the attained-
age covariate which RERF obtained by weighting each
individual contribution by its p-y within the cell. Likewise
agex is the p-y weighted mean age-at-exposure, since is
the difference between year, the p-y weighted mean cal-
endar time, and the exposure date (depending on city),
and birth is defined as year - age. The dataset also con-
tains sex, city, and distcat, the latter taking the values 1
(urban), 2 (rural), and 3 (Not in City). The grouped data
is stratified by these (and other) categories. The dataset
is then restricted by sex = 2, and by distcat < 3 if the
NIC group is excluded; city and distcat are converted
to factor variables fc and fd. For convenience, covariate
names are introduced in bold, but then used in normal
font.
When modelling all solid cancers, the instantaneous
flash dose is the p-y weighted mean colon dose in mGy,
defined as coldose = 1000*cola02w10 using the DS02
dosimetry and a Relative Biological Effectiveness (for
neutrons) of 10, unless otherwise specified. The dataset
is then restricted by coldose < 100 (or < 20 or <
500). For convenience A+-, B+- and C+- refer to 0 –
20 mGy, 0 – 100 mGy and 0 – 500 mGy subcohorts
including or excluding NIC. Weighting each coldose by
the py of its data cell, the mean coldose in A+-, B+-
and C+- is 2.43, 3.70, 9.84, 13.85, 36.44, 48.93 mGy
respectively.
More generally, modelling uses the appropriate organ
dose as in [1] and LSSinc07. Tissue weighting factors are
not applied. When considering a cancer group or site,
dose refers to the relevant p-y weighted organ dose in
mGy, and the response variable obs is the number of
incident cases of that cancer in each data cell. The case
numbers by site and dose range are shown in Table 1. Note
that A+- etc. are defined from coldose, no matter which
cancer site is under consideration.
Modelling seeks to predict the cancer risk, i.e. the
expected value of obs/py, as a function of covariates and
their interactions. Each data cell is regarded as an inde-
pendent source of Poisson distributed incident cases, and
penalised regression with cubic splines, using a log link,
is used to estimate the expected value of obs. Briefly
(see [21]):
obsj ∼ Pois(μj) where j indexes the data cells
log(μj) =
∑
iβ ifi(xj) where i indexes the model compo-
nents f and coefficients β ; fi is a function of covariates
x, whose form is specified in the model but whose value
varies with xj in cell j; and β i is a numerical coefficient of
fi, independent of j, to be estimated during model fitting.
The fi can include offsets, whose β i is fixed at 1; factors;
parametric terms; splines derived from the covariates; and
tensor products of such splines.
A cubic regression spline with components f0, f1. . . fk-1 is
obtained from covariate x by placing k knots, for example
at equally spaced quantiles of x, forming the natural cubic
splines with value 1 at the specified knot and 0 at the other
knots, using a centering constraint to achieve
∑
jfi(xj) = 0
when i > 0, and setting f0 = 1.
During model fitting, the β i are estimated by min-
imising the penalised deviance, Dev + βTSβ , where the
positive semi-definite penalty matrix S is a direct sum of
blocks generated from the splines, each block incorporat-
ing a smoothing parameter λb. For tensor product splines,
there are separate smoothing parameters for each margin.





where Iobs = 1 if obs > 0 and 0 otherwise
Minimising the penalised deviance is a compromise
between approximating the data (lowering Dev), and
the “wiggliness” of the fitted model as measured by
the penalty. Higher values of the smoothing parame-
ter(s) impose stronger penalties, making the fitted model
smoother with lower “effective degrees of freedom” (a
penalised version of the number of independent parame-
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Table 1 Case numbers by site and dose range
Site A- A+ B- B+ C- C+ Mid age Mid agex Mid since
Solid 4239 6271 5474 7506 6712 8744 68.4 33.1 36.9
Adeno 2477 3722 3188 4433 3928 5173 67.0 28.3 38.6
Othepi 1016 1460 1310 1754 1583 2027 73.3 38.4 32.7
Squam 550 823 718 991 881 1154 63.5 33.2 28.6
Digest 2206 3263 2825 3882 3418 4475 71.7 33.5 38.6
Genital 660 1008 871 1219 1035 1383 61.8 31.6 28.6
Resp 324 487 441 604 558 721 73.2 36.5 38.6
Stom 997 1459 1285 1747 1564 2026 71.6 36.6 33.6
Colon 373 578 471 676 570 775 71.7 29.3 44.1
Liver 287 416 356 485 433 562 71.7 32.6 41.4
Gall 181 266 234 319 273 358 73.2 36.8 38.6
Panc 134 192 172 230 208 266 73.4 36.6 38.6
Rect 183 283 245 345 291 391 68.5 31.6 41.3
Uterus 519 806 689 976 821 1108 61.7 31.5 28.6
Cervix 384 598 509 723 603 817 61.8 31.7 28.5
Corpus 84 132 108 156 126 174 61.1 23.1 38.5
Ovary 115 170 143 198 171 226 63.5 31.6 33.6
Breast 441 667 554 780 713 939 59.1 22.4 38.6
Lung 290 437 396 543 503 650 73.3 36.4 38.6
Thyroid 158 219 203 264 271 332 66.7 28.2 31.9
Cns 93 117 125 149 151 175 66.2 26.7 37.0
Mid age (agex, since) is the age (agex, since) below which 50% of cases occur.
Values are shown for B+, and are similar for other dose ranges
ters), but allowing it to stray further from the individual
data points. As λb → ∞, the model becomes log-linear
(only the linear components of the spline terms are unpe-
nalised by S).
Model fitting involves optimising the smoothing param-
eters affecting S, through a criterion such as General-
ized Cross Validation, RestrictedMaximumLikelihood, or
Marginal Likelihood (see [21, 24] for details). After fitting,
inference is based on the Bayesian posterior covariance
of β .
With the fitted βˆi, the expected value of obsj is μj =
exp(
∑
iβˆ ifi(xj)). The fitted model also predicts the
expected value μj,0 if the dose covariate is reset to 0 while
preserving all other covariates and the βˆ i. In each cell,
baseline risk is estimated internally from the fitted model
as μj,0 / pyj and Relative Risk is RRj = μj / μj,0.
From here on, models are defined and fitted using the R




obs ∼ offset(log(py)) + (fc + fd)∧2
+ti(logage, k = 10) + ti(birth, k = 10)
+ti(logage, birth, k = 10),
family = "poisson",method = "ML" )
The reverse arrow <- defines the model by the subse-
quent expression, with gam denoting a generalized addi-
tive model. Here, obs is regarded as a sample from a
Poisson distribution whose mean, varying across the data
cells, is specified with a (default) log link. The offset term,
with coefficient fixed at 1, ensures that the fitted value
of obs/py is independent of py. The factor variables and
their first order interaction are included as (fc+fd)ˆ2. The
smooth term ti(logage) refers to an unknown linear com-
bination of splines derived from logage, and the tensor
product term ti(logage, birth) allows for interaction of
logage with birth. In each smooth, the basis dimension is
set at 10. By default, “cubic regression splines” are used
with the ti terms. The smoothing parameter optimisation
method indicated by "ML" is Marginal Likelihood. For
details see [21] and ?gam and ?ti (within mgcv). Setting
family = "quasipoisson" allows a mean-variance relation
V=μφ where V is the variance about mean μ and φ > 0
is a scale factor. For the Poisson family, φ = 1, but any
positive scale can be set, or estimated as below.
The dose covariate is highly skewed and, in the grouped
data, multimodal. Over 70% of py in the full data has dose
< 20 mGy, or over 60% if NIC cells are excluded. Like-
wise over 84% has dose< 100 mGy, or 79% if NIC cells are
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excluded. The grouped data cells are also stratified by dose
category, an analytical decision embodied in the anony-
mous public data. For example, each cell in A- or A+ will
contain records with dose either below 5 mGy or between
5 and 20 mGy.
To adjust for this irregular distribution, when dose = D
define ecdos as the proportion of cells with dose ≤ D,
a monotone increasing function of dose with an approx-
imately uniform distribution. It increases quickly where
dose is concentrated, remaining static where dose is
sparse. While max(ecdos)=1, min(ecdos) > 0 due to
cells with dose = 0. Formally, ecdos is the empirical
cumulative distribution function of dose, obtained in R
as ecdf(dose)(dose), with inverse transformation quan-
tile(dose,). Figure 1 shows ecdos and dose in B+.
The initial model P0 (and its quasipoisson variant Q0)
are enlarged with terms using ecdos or dose and interac-
tions, as shown in Table 2.
The nested chains P0 ⊂ P2e ⊂ P3e ⊂ P5ae, P0 ⊂ P2e
⊂ P4ae ⊂ P5ae, P0 ⊂ P2e ⊂ P3e ⊂ P5se, and P0 ⊂
P2e ⊂ P4se ⊂ P5se give models of increasing complexity
using ecdos with agex or since respectively. Correspond-
ing nested chains P0 ⊂ P2d etc. are defined using dose
instead of ecdos. P2 refers to the pair P2e and P2d, etc.
The scale for a quasipoisson model M is estimated iter-
atively via Pearson χ2 = ∑(obs − fit)2/fit, where fit is
the fitted value, by seeking φˆ  χ2/dfres where dfres is
the residual degrees of freedom (# of records – effective
degrees of freedom).
Additional file 1: Appendix A describes methods for
Relative Risk RR, confidence intervals based on the
Bayesian posterior distribution of β , dose response
curves, and model selection. Simulation tests used to
choose the preferred method of smoothing parameter
optimisation and to validate the models are outlined in
Additional file 1: Appendix B.
Numerical results are given at 2.5 and 10 mGy in A+-,
2.5, 10, 20, 40, 60, 80 mGy in B+-, and at 2.5, 10, 100,
200, 300, and 400 mGy in C+-. Confidence intervals are
90% (lower and upper 95% confidence limits LCL95% and
UCL95%) unless otherwise specified, and “borderline”
denotes 0.98 ≤ LCL95% ≤ 1.
Initially, no minimum value of the smoothing param-
eters was imposed. However, if the visual output was
“too wiggly”, indicating overfitting, min.sp was increased
until the output appeared fairly smooth, a subjective
judgement.
In each data cell, a fitted model gives predicted values
μ, with
∑
μ = ∑ obs, and predicts values μ0 if dose
had been reset to 0, or ecdos reset to ecdf(dose)(0). The
attributable fraction 1−∑μ0/∑μ is the predicted num-





μ0 estimates the Standardized
Incidence Ratio from the fitted model.
The age distribution of cases varies between cancer
sites. Define the “mid” age (and agex, since) for a site
and dose range as that below which half the cases occur.
Table 1 includes the mid values by sites in B+; values
for other dose ranges are similar. Results are reported at
the mid age rounded to the nearest 5 years, and where
appropriate at the rounded mid agex or since.
For a fitted model M, set IM = 1 on any data cell for
which LCL95% > 1, and 0 otherwise. The proportion of
obs (or py) for which IM = 1 measures the extent to which
RR > 1 is significant across the dose range. Since IM =
0 if dose = 0, the proportions are obtained for D0, those
cells with dose > 0, or for D0.5 (dose > 0.5 mGy). Corre-
sponding proportions are obtained on S0.5 (since< 35 and
dose > 0.5 mGy), or T0.5 (agex > 35 and dose > 0.5 mGy),
or S0.5 ∩ T0.5. Likewise, the indicator JM = 1 on any data
cell for which UCL95% < 1, and 0 otherwise. The propor-
tion of obs (or py) for which JM = 1 measures the extent to
which RR < 1 is significant across the dose range.
Selected models for all solid cancers were re-fitted after
excluding exceptional data points as detected by Cook’s
Distance, or with thin plate regression splines, or for
urban residents, or with RBE as obtained in [25].
For a fitted model M, influence(M) is a vector of lever-
age at each cell, and plotting influence(M1)/influence(M2)
against dose comparesmodel sensitivities in different dose
regions. The ability of ecdos and dose models to detect
hypothetical dose-responses was compared by simula-
tion (Appendix B). Further simulations considered the
uncertainty in dose.
Fig. 1 Empirical cumulative distribution of dose. The ecdf of dose, denoted ecdos, is plotted against dose in B+ (0 - 100 mGy including Not in City).
The histogram is approximately uniform. py and case fractions are plotted against dose and ecdos
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Table 2 Model definitions
Model Family φ Model Family φ Terms
P0 poisson 1 Q0 quasipoisson > 0 offset(log(py))+(fd+fc)ˆ2+ti(logage) +ti(birth)+ti(logage,birth)
P1e poisson 1 Q1e quasipoisson > 0 .+ecdos
P2e poisson 1 Q2e quasipoisson > 0 .+ti(ecdos)
P3e poisson 1 Q3e quasipoisson > 0 .+ti(ecdos)+ti(ecdos,logage)
P4ae poisson 1 Q4ae quasipoisson > 0 .+ti(ecdos)+ti(ecdos,agex)
P4se poisson 1 Q4se quasipoisson > 0 .+ti(ecdos)+ti(ecdos,since)
P5ae poisson 1 Q5ae quasipoisson > 0 .+ti(ecdos)+ti(ecdos,logage) +ti(agex)+ti(ecdos,agex)
P5se poisson 1 Q5se quasipoisson > 0 .+ti(ecdos)+ti(ecdos,logage) +ti(since)+ti(ecdos,since)
P1d poisson 1 Q1d quasipoisson > 0 .+dose
P2d poisson 1 Q2d quasipoisson > 0 .+ti(dose)
P3d poisson 1 Q3d quasipoisson > 0 .+ti(dose)+ti(dose,logage)
P4ad poisson 1 Q4ad quasipoisson > 0 .+ti(dose)+ti(dose,agex)
P4sd poisson 1 Q4sd quasipoisson > 0 .+ti(dose)+ti(dose,since)
P5ad poisson 1 Q5ad quasipoisson > 0 .+ti(dose)+ti(dose,logage) +ti(agex)+ti(dose,agex)
P5sd poisson 1 Q5sd quasipoisson > 0 .+ti(dose)+ti(dose,logage) +ti(since)+ti(dose,since)
Models use cubic regression (cr) splines, with basis dimension 10
Model fitting by method ML
“.+” : augment the initial model P0 (or Q0) by the terms which follow
ti refers to a smooth term on the enclosed covariate(s)
These intensive computations were applied only for
all solid cancers. Elsewhere, the Bayesian posterior CIs
(Appendix A) are reported without further validation.
Some codes with commentary are shown as additional
files.
Results
For all solid cancers, no minimum smoothing parame-
ters were imposed. Basis dimension k=10 was sufficient
when tested by gam.check or modelling residuals against
covariates. TheMLmethod of smoothing parameter opti-
misation was preferred to alternatives, giving 95% CIs
which performed well under simulation tests described in
Appendix B and shown in Fig. 2. ML is discussed in [24].
P5ae, P5se, P5ad and P5sd were cross-validated
(Appendix B) in A+-, to test the proportion of deviance
explained and the estimated RR|10 mGy with 90% CIs, see
Additional file 1: Table S1.
Additional file 1: Figure S1 shows the dose response
in B+. All plots show RR significantly raised, although
the response is lower with the dose models. Plots with
REML or GCV.Cp optimisation methods are similar. For
the ecdos models, the appearance of the response reflects
the relation between ecdos and dose (see Fig. 1); corre-
sponding curves of RR against ecdos are regular.
Figure 3 compares the responses of P5se and P5sd in A+,
B+ and C+, evaluated at age 70 and since 35. Curves are
similar over A-, B- and C-, and for P5ae and P5ad at age 70
and agex 35, with slightly weakened significance.
Data simulated over B- from a variety of hypothetical
forms of the true dose-response curve, without interac-
tions, was fitted with P2e and P2d (Appendix B). Table 3
has results for 10 curves, comparing models by the mean
coverage of their respective CIs across the dose range.
Models with ecdos give better or equivalent coverage,
unless the true dose-response is linear.
Figure 4 displays the simulated geometric mean fitted
values and CIs for two of these curves (R1 and C2), show-
ing that the dose model underestimates the true response
while the ecdos model captures it correctly.
The increased sensitivity of ecdos models at low doses
is seen in Additional file 1: Figure S2, plotting the ratio of
influence with P5sd to that with P5se, against dose. In B+-
and C+- low doses have less influence on P5sd, reducing
its sensitivity to their effects.
Splines constructed from ecdos have better variability
than dose splines at very low doses, lowering the internal
baseline estimates. Additional file 1: Figure S3 compares
splines from P2d, P2e, and P2g constructed from gdos, a
smooth approximation to ecdos, when modelling over B+.
Although the P2g response curve is simpler, the param-
eters of gdos vary with dose range and its distribution is
multimodal, whereas ecdos has a universal definition and
an approximately uniform distribution.
Interactions in B+ are shown by perspective plots in
Fig. 5, fitting P5a and P5s with either ecdos or dose, and
fixing age = 70 or agex = 35 or since = 35. Figure 6 shows
RR|10 mGy and 90% CIs at age 70, using P5a and P5s fitted
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Fig. 2 Optimisation methods and Bayesian posterior confidence intervals. For all solid cancers in A- (0 - 20 mGy excluding NIC), the model P4se (see
Table 2) is fitted with smoothing parameter optimisation by GCV.Cp, ML, and REML. At 35 years time-since-exposure, Relative Risk is shown by grey
curves, and 95% Bayesian posterior confidence intervals (Appendix A) are shown by blue and red curves. Simulation gives estimates of coverage,
Bootstrap-t CIs (triangles), and an alternative CI (large circles) stretched to achieve 95% coverage (Appendix B), with stretch factors as shown in the
plot key
over A+, B+ and C+. With P5a at age 70 RR increases with
agex at all doses in A+-, B+- or C+-. With P5s at age 70,
RR decreases (or is constant) with since at all doses. The
decrease is confined to since> 35 in C+-. With P5a at agex
35 RR generally decreases (or is constant) with age. With
P5s at since 35 RR increases (or is constant) with age in
A+- and B+-, but decreases with age at higher doses in C+-.
Poisson model selection methods (Appendix A) were
applied to choose preferredmodels. P5se is preferred in all
six dose ranges by method 1 (lowest ML score). The three
methodschosemodelswithecdos in17of18cases.Additional
file 1: Table S2 shows the preferred Poisson models for
each range and selection method. As appropriate, RR is
shown at age 70, agex 35, or since 35. All preferred models
show RR elevated at 2.5, 10, 20, 40, 60, 80, 100, 200, 300,
and 400 mGy, with LCL95% > 1, except for method 2 in
B+ where P3d is preferred, with LCL95% ≥ 1. In all cases
Deviance < dfres. The proportion of Deviance explained
Fig. 3 Dose response of preferred models in A+, B+, C+. For all solid cancers, the top row shows the Poisson model P5se selected in each dose range
to minimise ML, with the corresponding dose model P5sd on the bottom row. RR and 90% CIs at the rounded mid since and age, are plotted
against dose. ML scores, effective degrees of freedom, and Deviance are listed. For model definitions see Table 2
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Table 3 Coverage by P2e and P2d of true dose response
Name ERR β σ τ γ Form Mean (lhe) Mean (lhd)
N1 g(d,β , σ , τ) 0 0 null 95.18% 94.90%
L1 g(d,β , σ , τ) 0.002 0 linear 81.46% 94.56%
H1 f (d,β , σ , τ) 0.004 -0.2 0.05 hormesis 75.08% 69.86%
P1 f (d,β , σ , τ) 0 0.2 0.05 plateau 93.36% 69.68%
C1 f (d,β , σ , τ) 0.0012 0.08 0.5 two phase 90.88% 50.08%
C2 f (d,β , σ , τ) 0.015 0.75 0.2 two phase 94.80% 13.98%
R1 g(d,β , σ , τ) 0.002 0.01 0.08 two phase 93.64% 68.14%
R2 g(d,β , σ , τ) 0.002 0.01 0.04 two phase 93.98% 66.10%
T1 h(d, γ ) 50 threshold 88.40% 87.66%
T2 h(d, γ ) 25 threshold 86.88% 86.90%
All Solid cancers, fitting over B-
ERR: true value as specified by function
f (d,β , σ , τ) = β · d + σ · (1 − exp(−τ · d))
g(d,β , σ , τ) = β · d + σ · d · exp(−τ · d)
h(d, γ ) = ifelse(d<γ , 0, 1/5 · ((d − γ )/(100 − γ ))3)
Mean (lhe or lhd): mean coverage at 10, 20. . . 100 mGy of 95% CI for P2e (P2d) see also Appendix B
varies from 46.1% in C- to 68.1% in A+. The attributable
fraction varies from 1.4% (method 2 in B+) to 9.4% in A-.
Additional file 1: Table S2 also shows the percentage of
cases and py in D0 for which RR > 1, LCL95% > 1, or
UCL95% < 1; likewise for cells in D0.5, S0.5, T0.5, or S0.5
∩ T0.5 (see “Methods”). For each of these preferred mod-
els, cell and dose ranges, RR > 1 holds for over 80% of
cases and py, and UCL95% < 1 never occurs. Except with
method 2 in B+, LCL95% > 1 holds for over 70% of cases
in T0.5, over 75% of cases in S0.5, and over 90% of cases in
S0.5 ∩ T0.5.
Significant elevation of RR persists over a wide range
of age and since (or agex), as shown for all models in
B+ in Fig. 7. With the ecdos models, RR is significantly
raised for regions containing age > 55, agex > 35, or since
< 35. With the dose models, the regions of significance
are similar, though smaller. For the preferred (method 1)
Poisson models in A+, B+, and C+, Fig. 8 shows the dose
response, the dependence of RR on since and age, and the
regions of significance.
The dose models themselves give non-linear responses
over C+ (see Fig. 3). With P2d, RR rises approximately
linearly below 150 mGy, before tapering. Anova com-
parison with P1d, in which dose appears as a log-linear
unsmoothed term, gives p = 0.015. Below 100 mGy, the
Excess Relative Risk (ERR = RR - 1) is about 70% higher
with P2d than with P1d. With P5sd RR tapers above
150 mGy as with P2d. The term ti(since) has e.d.f. =
3.658 and p = 0.037, and anova(P3d, P5sd) = 0.008 while
anova(P4sd, P5sd) = 0.07. Thus P5sd is decidedly non-
linear in dose, whose interaction with logage is borderline,
but since has significant impact.
Fig. 4 Ability to capture a known response. Data is simulated (Appendix B) over B- with RR = 1 + ERR as specified by the formulas in Panels a and c,
without interactions. Thick black curves show the true RR. Simulated data is modelled by P2e (Table 2) in Panels a and c, and remodelled by P2d
(Table 2) in Panels b and d. At dose = 10, 20... 100 mGy, fitted values and 90% CIs are obtained at each simulation step. Coverage is the % over all 10
doses for which the simulated CI contains the true RR. Panels display the geometric means (hollow dots) interpolated by smoothing splines, green for
fitted values, blue (red) for lower (upper) 95% CIs
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Fig. 5 Interaction perspective plots in B+. For all solid cancers in B+, the ecdos and dose versions of P5a and P5s (Table 2) are fitted. The top row
shows RR (z-axis) as a joint function of ecdos or dose (y-axis) and agex or since (x-axis), at age 70. Below, RR is shown as a function of ecdos or dose
and age, at agex 35 or since 35. Shadings from purple to gold show increasing RR
The dose models also show RR raised in A+-. For P1d
and P2d, in both ranges RR|10 mGy = 1.09 (0.99 , 1.19). P4sd
is preferred amongst dose models by methods 2 and 3. At
since 35, in A- RR|10 mGy = 1.11 (1.00 , 1.22) with signif-
icant elevation when since < 35. In A+ RR|10 mGy = 1.09
(0.99, 1.19) with significant elevation when since < 32. In
A+- P5sd is preferred amongst dose models by method 1.
At age 70, since 35 in A- RR|10 mGy = 1.11 (1.00 , 1.23)
whilst in A+ RR|10 mGy = 1.11 (1.01 , 1.22) and RR is signif-
icantly raised for 37.2% (28.2%) of cases (py) in D0.5, 75.0%
(42.3%) in S0.5, and 68.4% (79.6%) in T0.5 .
In general, point estimates and CIs are primarily
affected by the dose range (less by the inclusion of NIC)
and the choice of dose or ecdos.
The stability of these results was tested, first by using
thin plate regression splines. RR and CIs were simi-
lar to those shown in Additional file 1: Table S2, but
cubic regression splines gave lower ML scores. If excep-
tional cells detected visually by Cook’s Distance (CD) are
deleted, RR values and 90% CIs were slightly altered from
those in Additional file 1: Table S2, but still significantly
raised (borderline for B+ method 2). Deletion affected
Fig. 6 Interactions at 10 mGy. For all solid cancers in A+, B+, and C+, RR and 90% CI at 10 mGy is plotted against agex or since, at age 70, for the
ecdos and dose versions of P5a and P5s (Table 2). The top row shows ecdos models, with corresponding dose models below
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Fig. 7 B+ significance regions. For all solid cancers in B+, Poisson ecdos and corresponding dose models (Table 2) are plotted on the top and
bottom rows. RR and 90% CIs are shown for P2e and P2d. For the interaction models, covariate pairs are shaded red if the lower confidence limit
LCL95% > 1, brown if RR > 1 but LCL95% ≤ 1, blue-grey if RR ≤ 1 but UCL95% ≥ 1, and bright blue if the upper confidence limit UCL95% < 1 (none
occur here). T denotes the region with agex > 35, and S the region with since < 35. Points with dose ≤ 0.5 mGy are omitted
the choice of preferred models only for C-, where P5ae
was preferred by all methods, and C+, where P5se was
preferred by all methods. When preferred models were
refitted after excluding cells with the highest 5% of CD
values, RR was raised with at least borderline significance
across each dose range.
The combined impact of sampling variability and log-
normal dosimetry errors was simulated (see Appendix B)
using P5se and P5sd in A-, shown in Additional file 1:
Figure S4. Geometric mean fitted values and 90% CIs are
below the values derived from the original data, but still
raised with borderline significance; while bootstrap-t [26]
and stretched CIs derived from the simulated data remain
significantly raised.
Models were fitted with RBE as the function of neutron
dose Dn shown in [25] (Fig. 4 and Eq. (2)). This raises
Fig. 8 A+, B+, C+ preferred Poisson models, interactions and significance regions. For all solid cancers in A+, B+, C+, the Poisson model P5se (Table 2)
minimises ML. RR and 90% CIs are shown at age 70 and since 15 or since 35. RR is plotted against since at age 70, and against age at since 35.
Covariate pair shadings are as in Fig. 7, omitting points with dose ≤ 0.5 mGy
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the dose assigned, as RBE > 50 in the ranges considered
here (for which Dn < 0.003 Gy). Results are shown in
Additional file 1: Table S3. In all dose ranges and with all
three methods of Poisson selection, RR is elevated with at
least borderline significance. In 15 out of 18 cases, and for
6 of 6 with method 1, the same models are selected, and
RR and CIs are slightly lower but still comparable to those
in Additional file 1: Table S2.
Excluding genital or, separately, respiratory cancers, the
remaining solid cancers were modelled over A+, B+, and
C+, with results in Additional file 1: Table S4. RR estimates
are mainly similar to those in Additional file 1: Table S2.
The heightened significance when agex> 35 or since< 35
generally survives these exclusions.
For urban residents in A, B, or C, the preferred Pois-
son models show RR elevated with at least borderline
significance, and a tapering response at higher doses (see
Additional file 1: Table S5). With method 3, RR is signifi-
cantly elevated in each range.
In each dose range, the factor variables fc and fd
have significant interaction, lowering the fitted values
for rural Nagasaki residents. Modelling separately by city
(Additional file 1: Table S6), for Hiroshima, models with
since are preferred for every dose range and selection
method. None show RR significantly or borderline raised
at rounded mid age and since over A+- or B+-, but over
C+- RR is significantly raised (method 1) or borderline (at
10 mGy, methods 2 and 3) at age 70 and since 35, and
significantly raised (all methods) for high percentages of
cases and py.
For Nagasaki, the preferred models show RR signifi-
cantly raised in A+- and B- (and for method 1 in B+) at
rounded mid age, since, or agex, and for high percent-
ages of cases and py. Similar results are obtained over C+
with method 1, though exposure at younger ages appears
more significant. Figure 9 shows the response by city at
the respective rounded mid age and since or agex for the
preferred models (method 1) in A+, B+, and C+, and the
variation of significance with covariates.
Specific sites were analyzed by quasipoisson models
with the Pearson estimate of scale φˆ. Additional file 1:
Table S7 gives details for Q2 in B+ at 21 sites, using
scale estimates from Q2e and Q2d with identical values of
min.sp. The ML score of Q2d at φˆQ2d is compared with
that of Q2e refitted at φˆQ2d, and vice-versa. The same
covariate was preferred whichever optimised scale was
used. TheQ2 response curves and preferred covariates are
shown in Fig. 10. Q2e curves are smoothed for display.
Several sites, including the uterus, show non-linear
responses. For all solid, genital, respiratory, gallbladder,
thyroid, and cns, the response is significantly elevated for
bothmodels in all cells in D0.With the preferred covariate,
RR is also significantly elevated throughout D0 for the
uterus and corpus, with weaker evidence for squamous,
cervix, and rectum. For lung cancers, using the preferred
covariate RR is elevated with borderline significance for
over 80% of py in D0.
These 12 sites, along with the breast and liver which are
radiosensitive at higher doses but show (non-significant)
negative response in Fig. 10, were analysed with inter-
action models. In Additional file 1: Table S8, method 4
is used for each site and dose range, to choose the pre-
ferred quasipoisson model. Poisson selection by methods
1, 2, and 3 is also shown. Using the preferred quasipoisson
models, RR and 90% CIs are shown along with the per-
centages of cases and py in D0, D0.5, S0.5, T0.5, and S0.5
∩ T0.5 for which RR is elevated, significantly elevated, or
significantly lowered.
RR is significantly elevated across the dose range for all
solid cancers in A-, A+ (borderline), B+-, and C+-. Squa-
mous cancers show significantly elevated RR in A-, B-,
B+ (borderline 80 mGy), and C+-. The corpus has signif-
icant, highly elevated RR in A+- and B+-. Thyroid RR is
significantly elevated in A+-, B+-, and C+-.
Respiratory RR is significantly lowered for 37.2% of py
in A- (all with agex < 18), 13.7% of py in A+ (all with
since > 44) and 11.9% of py in C- (all with agex < 8); it
is significantly raised in S0.5 and T0.5 in B+-, and in D0.5,
S0.5 and T0.5 in C+-. For the breast, RR is significantly
lowered only for 10.9% of py in B-. There is little signifi-
cant elevation in A+- or B+-, but RR is significantly raised
in D0.5, S0.5 and T0.5 in C-, and for all py in C+. For the
liver, RR is significantly lowered for 24.8% of py in A-,
26.2% in A+, 8.7% in B-, 5.6% in B+, 10.1% in C-, and 2.2%
in C+.
Additional file 1: Figures S5–S10, for respiratory, uterus,
and thyroid, correspond with Figs. 7 and 8 for all solid can-
cers. For the uterus, RR is a U-shaped function of age. For
the thyroid, RR peaks around age 60 and decreases with
agex.
Whilst the preferred models vary over the sites, dose
ranges, and selection methods, ecdos models are cho-
sen in 215 out of 336 cases, with a similar proportion
for each selection method. Models with since are cho-
sen in 194 cases and models with agex are preferred in
80. Among the 24 models for all solid cancers, ecdos is
chosen in 22, since in 18, and agex only once. Overall,
there is a clear preference for ecdos and since, and models
with both covariates are preferred in 140 of 336 cases in
total.
The male cohorts in A+ and B+ were fitted with Pois-
son models. In A+, P5ad (method 1), P4ae (method 2)
and P2e (method 3) are preferred. With P5ad at age
70 and with P4ae, the response increases with agex but
lacks borderline significance. With P2e the response is
insignificant. In B+, P5se (method 1), P4se (method 2) and
P2e (method 3) are preferred. With P5se at age 70, the
response decreases with since but fails to reach borderline
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Fig. 9 Hiroshima and Nagasaki. For all solid cancers over A+, B+, C+, modelling is carried out separately by city, selecting the Poisson model to
minimise ML in each case. In the top row, RR and 90% CIs are shown at the rounded mid age, agex or since as appropriate. In the bottom row,
covariate pair shadings are as in Fig. 7, omitting points with dose ≤ 0.5 mGy
significance. With P4se, the response decreases with since
and is borderline for since ≤ 20. With P2e, the result is
insignificant.
The combined cohorts in A+ and B+ were fitted with
Poisson models, controlling for gender, city, distcat and
their first order interactions, obtaining a gender aver-
aged dose response. In A+, P5sd (method 1) and P4sd
(methods 2 and 3) are preferred. For P4sd at 10 mGy RR
is significantly raised (90% CIs) when since ≤ 33. At since
30, RR|10 mGy = 1.09 (1.02 , 1.17). Results from P5sd at
age 70 are nearly identical. In B+, P5se (method 1) and
P4se (methods 2 and 3) are preferred. For P4se at since 30,
RR|10 mGy = 1.07 (1.01 , 1.12), but significance is lost for
19 ≤ since ≤ 27.
Discussion
Low dose radiation has significant effects at cell level
including some non-linear responses [27], but cancer
Fig. 10 Quasipoisson modelling of specific sites. In B+, the simplest quasipoisson models Q2e and Q2d (Table 2) are fitted to all solid cancers and
specific sites. In each case, a preferred version is chosen to minimise ML when each model is refitted at the scale optimised for the other member of
the pair. The preference is indicated by e or d in the panel title, and its RR and 90% CI are shown in bold while the unselected model is displayed in
the background
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risk is typically modelled as a linear function of dose
and the risk below 100 mGy is still under debate. The
body’s multiple defences may filter out most abnor-
malities and the dose-response for disease could be
linear.
In analysing the Japanese A-bomb survivors incidence
or mortality, the Lifespan studies and other reports
[1, 3, 28, 29] use a form of Poisson regression in which
ERR = RR - 1 is modelled as βD, where β may be modified
by sex, age and age-at-exposure through other parame-
ters; alternatively, ERR ∼ βD + γD2. If the response were
known to take a specific form with the same parameter
values at all doses, a model fitted to the full data could pre-
dict risk at 0.01 Gy. Otherwise, a model which estimates
risk at 1 Gymay be inappropriate at lower doses, as several
studies recognise [2, 8, 30].
In one approach to detecting non-linearity, numerical
data can be reduced to categories before smoothing the
results [1]. The outcome may depend on the cut points,
and information is discarded by categorising data. The
Generalized Additive Model [19, 21] is a more sophisti-
cated method. Using GAM, covariates and interactions
enter the model through unknown linear combinations of
splines.
The public data released by RERF is stratified by essen-
tially arbitrary dose categories with cutpoints 0, 5, 20,
40 mGy . . . as well as categories of age and age-at-
exposure, city, sex and location. However the data also
contains py-weighted mean values of dose, age, age-at-
exposure, and calendar year (giving time-since-exposure).
The analysis uses these values, whose distribution, partic-
ularly for dose, is far from uniform. Stratification causes
clumping of mean dose, but the individual exposures are
also concentrated at low doses. As Preston observed [1]
“One aspect of the LSS cohort that is often neglected is
the highly skewed dose distribution and the large number
of survivors who received low-dose, albeit at a high dose
rate, exposure.”
To compensate for stratification and skew, dose was
converted to its empirical cumulative distribution, a
monotone (invertible) transformation. The resulting vari-
able ecdos is approximately uniformly distributed. Models
using ecdos gave better fit for all solid cancers and many
specific sites. This transformation may still be relevant
with the individual data as dose remains skewed, though
no longer clumped.
If the true dose-response is linear then modelling with
dose is preferable. Whilst there is little difference in
detecting a threshold, ecdos models are better able to
capture alternatives, including plateau, hormesis, and a
variety of curves with rapid initial rise and a smaller
increase at higher doses. One such curve (Fig. 4 panels c
and d) is loosely based on in vivo data for γ -H2AX Foci
(see [31] (Fig. 1)).
The models have several sources of non-linearity,
including the log link, the relation between ecdos and
dose, and the splines. In fact, the fitted models are often
log-linear in ecdos as a main effect. However, the interac-
tion of ecdos or dose with logage and since or agex can
introduce further non-linearities.
For all solid cancers, in A+-, B+- and C+- all three Pois-
son selection methods yield models with RR raised across
the dose range at the rounded mid values of covariates,
with at least borderline significance. Results are stable
when deleting exceptional cells, simulating random errors
in dosimetry, adjusting RBE, using different splines, or
excluding genital or respiratory cancers. For all solid can-
cers, results are similar with Poisson or quasipoissonmod-
els, which explain around 68% of the deviance in A+, 58%
in B+, and 50% in C+.
For all solid cancers in A+-, all the dose or ecdos
Poisson models show effects which are at least bor-
derline (0.98 ≤ LCL95% ≤ 1) or significant (LCL95%
> 1) at 2.5 and 10 mGy, at the rounded mid values
of covariates. The preferred models with ecdos refine
the results. Significance persists over a wide range of
covariates.
With the Nagasaki data, the Poisson model cho-
sen to minimise ML shows RR elevated across the
cohort in A+-, B+-, and C+; and in B+- ERR|10 mGy is
more than twice the value for the combined cohort.
Using a very different approach, Sasaki [7] found
an exceptional dose response for Nagasaki (male and
female).
For all solid cancers, risk estimates are similar with
or without the Not In City data. NIC cells are not dis-
tinguished by the urban/rural status of the individual
members’ normal residence, which makes a significant
contribution to the model. Even without including NIC,
extremely low non-zero doses arise from distant rural
residents. However, including NIC gives more cases and
greater statistical power.
For all solid cancers and most individual sites, time-
since-exposure was a better predictor than age-at-
exposure. The fitted dependence of risk on since is not
governed by a latency threshold, and for all solid can-
cers, RR decreases with since at low doses. Risk could
rise with since < 12.4 years, the minimum value in the
cohort.
Shuryak [32] attributes childhood radiation risk to ini-
tiation when cells are proliferating, while older adult risk
arises from progression of previously acquired mutations.
For all solid cancers, RR increases with agex at low doses,
suggesting that for women, low dose radiation is acting
primarily via progression.
The risks found here are surprising, as linear extrap-
olation from [1] predicts much lower values at 10 mGy.
Preston’s Table 10 shows female ERR = 0.58/Gy with
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90% CI (0.43 , 0.69) at age 70 and agex 30 for solid
cancers in the 0 – 4 Gy (+ NIC) dose range (denoted
here as J+). Adjusting for age-at-exposure, at agex 35
ERR|1 Gy = 0.53 (0.37 , 0.67). Linear extrapolation gives
ERR|10 mGy = 0.0053 (0.0037 , 0.0067). Over B+, the ecdos
model P5se is preferred by method 1; at age 70 and since
35 RR|10 mGy = 1.068 (1.018 , 1.120), with ERR|10 mGy
12.8 times the extrapolated value. As Table 4 shows, in
A+-, B+-, and C+-, the four selection methods choose
ecdos models in 22 out of 24 cases, 90% CIs for
ERR|10 mGy exclude 0 in those cases and are borderline
in 2 cases, and in 23 cases the resulting estimates of
ERR|10 mGy are 9.6 – 45.7 times the prediction from linear
extrapolation.
However, the GAM Poisson models give estimates com-
parable with [1] when fitted over J+ and evaluated at 1 Gy.
Over this range, the preferred model (method 1, 2 or 3) is
P5sd. At 1 Gy, age 70 and since 35, RR = 1.80 (1.60 , 2.03)
while for P5ad at agex 35 RR = 1.56 (1.40 , 1.73), close
to Preston’s estimate and CI. The dose response in J+ for
P5ae, P5ad, P5se, or P5sd is roughly comparable with the
gender-averaged ERR shown in [1] (Fig. 3, using smoothed
category estimates from the 0 – 2 Gy data). Similar results
are obtained over J- (excluding NIC).
Table 4 Estimates of ERR at 10 mGy, age 70, agex 35, since 35
Sex Range Method Model Scale Covariates ERR|10 mGy, Female
90% CI, age 70,
agex 35, since 35 Ratio
MF 0–4 Gy LinExt from [1] 1 s,c,d,dose,age,agex 0.0053 (0.0037, 0.0067) 1.0
MF 0–0.5 Gy (urban) WtMovAv from [2] 1 s,dose,age,agex 0.02a (estimate) 3.8
F A- 1 P5se 1 c,d,ecdos,age,since 0.242 (0.057, 0.459) 45.7
F A- 2 P4se 1 c,d,ecdos,since 0.225 (0.045, 0.437) 42.5
F A- 3 P4se 1 c,d,ecdos,since 0.225 (0.045, 0.437) 42.5
F A- 4 Q4se 0.901 c,d,ecdos,since 0.228 (0.055, 0.430) 43.0
F A+ 1 P5se 1 c,d,ecdos,age,since 0.230 (0.054, 0.436) 43.4
F A+ 2 P5se 1 c,d,ecdos,age,since 0.230 (0.054, 0.436) 43.4
F A+ 3 P4se 1 c,d,ecdos,since 0.202 (0.032, 0.401) 38.1
F A+ 4 Q4sd 0.868 c,d,dose,since 0.088 (-0.001, 0.185) 16.6
F B- 1 P5se 1 c,d,ecdos,age,since 0.088 (0.017, 0.164) 16.6
F B- 2 P4se 1 c,d,ecdos,since 0.085 (0.015, 0.160) 16.0
F B- 3 P4se 1 c,d,ecdos,since 0.085 (0.015, 0.160) 16.0
F B- 4 Q4se 1.141 c,d,ecdos,since 0.077 (0.011, 0.148) 14.5
F B+ 1 P5se 1 c,d,ecdos,age,since 0.068 (0.021, 0.117) 12.8
F B+ 2 P3d 1 c,d,dose,age 0.013 (0.000, 0.026) 2.5
F B+ 3 P2e 1 c,d,ecdos 0.061 (0.015, 0.110) 11.5
F B+ 4 Q2e 1.102 c,d,ecdos 0.061 (0.013, 0.112) 11.5
F C- 1 P5se 1 c,d,ecdos,age,since 0.064 (0.038, 0.090) 12.1
F C- 2 P5ae 1 c,d,ecdos,age,agex 0.068 (0.045, 0.091) 12.8
F C- 3 P3e 1 c,d,ecdos,age 0.055 (0.034, 0.076) 10.4
F C- 4 Q3e 1.079 c,d,ecdos,age 0.051 (0.034, 0.068) 9.6
F C+ 1 P5se 1 c,d,ecdos,age,since 0.091 (0.055, 0.128) 17.2
F C+ 2 P4se 1 c,d,ecdos,since 0.057 (0.040, 0.075) 10.8
F C+ 3 P4se 1 c,d,ecdos,since 0.057 (0.040, 0.075) 10.8
F C+ 4 Q4se 1.066 c,d,ecdos,since 0.056 (0.039, 0.073) 10.6
MethodModel Selection Method
Model for P5se etc. see Table 2
LinExt Linear Extrapolation
WtMovAv Weighted Moving Averages
Covariates s=sex, c=city, d=distcat
Ratio ERR estimate from model / ERR estimate by Linear Extrapolation from [1]
aestimate from [2] Fig. 1
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At 1 Gy, the interaction of ecdos or dose with logage
and agex from fitting P5a over J+ is consistent with [1],
whose Fig. 4 is comparable with Fig. 11 here. If agex or
since is fixed, RR|1 Gy decreases with age. Preston’s Fig. 6
(using smoothed category estimates) is comparable with
the curve for 1000 mGy in Fig. 12 panel b (P5ad at age
70). At age 70, RR|1 Gy initially decreases with agex but
rises when agex > 40. Using P5sd, with better fit, at age
70 RR|1 Gy peaks at since 35. Similar curves arise at age 50,
but with higher values of RR.
However, the interactions at lower doses (see Figs. 5, 6,
and 8) conflict with the main model in [1], which has
RR decreasing with agex. At low doses, RR generally
decreases with age when agex is fixed, but increases with
agex when age is fixed. Likewise, above 100 mGy in C+ RR
decreases with age when since is fixed, but increases with
age in A+ and B+. At age 70, RR decreases with since in
A+ and B+ and when since > 35 in C+. In all the low dose
ranges considered here, RR increases with agex. Even in
J+, the curve for 100mGy does not decrease with agex (see
Fig. 12 panel b) Thus, the decrease of RR with agex (when
agex < 40) in [1] is specific to the higher dose range and
the response at 500 mGy or above.
Pierce and Preston [2] applied a simplified linear model
to the 0 – 500 mSv urban incidence data for both sexes,
finding a higher response than linear extrapolation would
predict. Their Fig. 1 shows a smoothed curve obtained as
a weightedmoving average of category estimates. The sex-
averaged RR at agex 30 and 100 mSv ∼ 1.09, from which
RR|female, 100mSv ∼ 1.12 as the fitted model has ERR|female
∼ 2*ERR|male. At agex 35, RR|female, 100mSv ∼ 1.10. Figure 1
suggests that RR|female, 10mSv ∼ 1.02. By comparison, the
preferred model (method 1) for the urban subcohort of C-
is P5se, and at age 70, since 35, RR|100 mGy = 1.14 (1.09,
1.18), while RR|10 mGy = 1.03 (1.02, 1.04). The interaction
with since is very weak, and the preferred model with
method 2 or 3 is P3e, for which at age 70 RR|100 mGy = 1.14
(1.09 , 1.19), as with the preferred quasi model Q3e. Mod-
els with either dose or ecdos show RR rising rapidly below
150 mGy before tapering, evidence of non-linearity in the
urban data below 500 mGy.
Furukawa and co-workers [8] analysed the combined
male and female incidence data below 400 mGy with
models including Linear Non Threshold, cubic smooth-
ing spline, and a Bayesian semiparametric piecewise linear
model, with dose responses at age 70, agex 30 shown in
their Fig. 1. The Bayesian and spline models gave simi-
lar responses at low doses. Whilst comparisons with the
Bayesian model are beyond the scope of this paper, the
spline model is roughly similar to P5ad, if dose knots
are set at 0, 5, 20, 40, 60, 80, 100, 125, 150, 175, 200,
250, and 300 mGy. Furukawa analysed the individual data,
but results using P5ad (with these knots) applied to the
public data below 400 mGy are not significantly differ-
ent. Figure 13 (panel a) shows the gender averaged dose
response for P5ad (knots). The spline estimate in [8] for
ERR|100 mGy = 0.03 (CIs are not shown for this model)
whilst for P5ad (knots) ERR|100 mGy = 0.07 (0.02, 0.11)95%.
The difference might result from the interaction struc-
tures in [8] which follow those in [1]. However, as Fig. 13
shows, the male response (panel b) lacks 95% significance
below∼ 300 mGy, but (panel c) female ERR|100 mGy = 0.11
(0.04 , 0.19). Panel d shows the ecdos model P5ae with
knots corresponding to those chosen for P5ad (knots).
Now ERR|100 mGy = 0.17 (0.10, 0.24).With the female data,
P5ae (knots) is preferred to P5ad (knots) by ML score
and AIC. At 10 mGy with 95% CIs, P5ad (knots) gives
ERR|10 mGy = 0.011 (-0.001, 0.023) whilst for P5ae (knots)
ERR|10 mGy = 0.052 (0.031, 0.074).
The values listed in Table 4 are obtained from preferred
models. P5ad is never selected, and P5ae is chosen only
once. Table 4 largely reflects the predominant selection of
ecdos models. Nevertheless, if P5ad and P5ae (with their
default knot locations) are fitted over A+ and evaluated
at 10 mGy, age 70 and agex 35, for P5ad RR = 1.10 with
90% CI (1.00, 1.21) while with P5ae RR = 1.21 (1.04, 1.41).
P5ae is again preferred to P5ad by ML score and AIC. The
default knots for P5ad in A+ are 0, 0.12, 0.33, 2.30, 2.57,
Fig. 11 0 – 4 Gy interactions with age at 1 Gy. For all solid cancers in the full female dataset including NIC, as in [1], RR at 1000 mGy is plotted against
age for the Poisson models P5ae and P5ad (Table 2), with agex fixed at 10, 35 and 60. Likewise RR at 1000 mGy is plotted against age for the Poisson
models P5se and P5sd, with since fixed at 15, 35, and 50
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Fig. 12 0 - 4 Gy interactions with agex and since. For all solid cancers in the full female dataset including NIC, as in [1], RR at 100, 500, 1000, 2000 and
3000 mGy is plotted against agex (panels a and b) for the Poisson models P5ae and P5ad (Table 2), with age fixed at 70, and likewise against since
(panels c and d) for the Poisson models P5se and P5sd
9.69, 10.55, 15.58, giving a much richer structure than 0,
5, 20. The estimate at 10 mGy when fitting P5ad over
A+ is much higher than the estimate when fitting P5ad
over C+.
Preston and co-workers [33] analysed the 1958–1998
solid cancer incidence data for exposure in utero or
early childhood (0 – 5 years), including NIC. For
women exposed in early childhood, at attained age 50
ERR|1 Sv = 2.2 (1.3, 3.4)95% (see [33] Table 5). Linear
extrapolation is comparable with results from P5sd over
Ci+ (agex ≤ 5, dose ≤ 500 mGy) at age 50 and since 45,
for which RR|10 mGy = 1.03 (1.01, 1.05)95%. With the pre-
ferred Poisson model (method 1) P5se, RR|10 mGy = 1.20
(1.06, 1.35)95%.Methods 2 or 3 select P2e, giving RR|10 mGy
= 1.14 (1.05 , 1.24)95%, while method 4 chooses Q2e giving
RR|10 mGy = 1.14 (1.06, 1.22)95%.
For site-specific risks, some studies of other cohorts
have found RR significantly raised after low dose exposure
to low LET radiation. Some evidence from the literature
on the thyroid, uterus and uterine corpus, is compared
with results from quasipoisson models applied to appro-
priate subcohorts here.
Direct evidence on thyroid cancer risk arises from
children given medical irradiation, residents affected by
Chernobyl, nuclear workers, radiotherapy patients, and
the A-bomb survivors. Except as indicated, these studies
applied a linear ERR model.
Additional file 1: Table S9 shows some results from
[1, 6, 7, 11, 13, 15, 34–37]. In each case, an appropriate
subcohort of the female incidence data was analysed for
comparison, using the simplest quasipoisson dose model
Q2d and the preferred quasi model for the subcohort,
chosen to approximate the dose and agex range in the
study, or with mean dose close to that at which risk was
reported.
In most cases, results from the subcohorts using either
model are compatible with the reported estimates, as
CIs overlap. There is striking agreement with the tinea
capitis studies. Sadetzki [34] used a linear model which,
at the mean dose, gives RR|93 mGy, female = 2.96 (2.07,
4.31)95%. Fitting the quasi models over C+ restricted to
agex < 16, Q2d gives RR|93 mGy = 2.30 (1.36 , 3.89)95%,
while the preferred model Q2e gives RR|93 mGy = 2.95
(2.05, 4.24)95%. The earlier study by Ron [35] included
Fig. 13 0 - 400 mGy male and female. For comparison with [8], panel a shows the dose model P5ad (Table 2) fitted to the 0 - 400 mGy male-female
data, with knots set at 0, 5, 20, 40, 60, 80, 100, 125, 150, 175, 200, 250, and 300 mGy. Gender averaged RR and 95% CIs are shown at age 70 and agex
30. Panels b and c show the male and female responses. Panel d shows the ecdos model P5ae with corresponding knots at ecdf(dose)(0),
ecdf(dose)(5) etc. ML scores and AIC for P5ad and P5ae fitted to the female data are shown for comparison
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the estimate RR|10 mGy = 1.27 (1.15, 1.42)95%. Fitting
the quasi models over B+ restricted to agex < 16, for
which the mean py-weighted dose = 10.7 mGy, Q2d gives
RR|10 mGy = 1.18 (1.06, 1.31)95%, and at the mean val-
ues of agex and age in [35] the preferred model Q5ad
gives RR|10 mGy, agex 7.4, age 37.6 = 1.28 (1.07, 1.53)95%. These
close agreements contrast with the differences seen in
the pooled study [11], where the tinea capitis estimates
appeared exceptionally high. However, the pooled esti-
mates are compatible with GAMmodelling on the appro-
priate subcohorts.
For Chernobyl survivors with agex < 18, Little [6] con-
sidered a linear-exponential model with low-dose asymp-
tote ERR = αD, estimating α = 9.72 (2.67, 94.31)95%. At
the geometric mean dose as reported in [38], this gives
an asymptotic RR|190 mGy = 2.85 (1.51, 18.92)95%. Fit-
ting the quasi models over C+ restricted to agex < 18,
Q2d gives RR|190 mGy = 2.62 (1.50, 4.57)95%. At the mean
attained age from [39], the preferred model Q3e gives
RR|190 mGy, age 23.7 = 4.27 (1.30, 14.02)95%.
Sasaki [7] reanalysed the incidence data in [1], with a
very different non-linear model. For the thyroid, from his
Fig. 3(i) ERR|0.1 mSv, female ∼ 0.35, though no CI or inter-
actions are shown. Results from C+ appear compatible.
The occupational study by Sont [13] did not estimate RR
for female thyroid cancer, but found a Standardized Inci-
dence Ratio = 1.42 (1.19, 1.69)90%. This was comparable
with internal estimates of SIR (see “Methods”), with CIs
by non-parametric bootstrap.
The results from GAM models applied to relevant sub-
cohorts are compatible with [6, 11, 13, 15, 34, 35]. They
are higher than extrapolations from [1, 36, 37], which
concerned higher dose ranges. However they appear com-
patible with [7].
Several studies found RR decreasing at higher doses. In
the radiotherapy studies, doses were high and the down-
turn was only apparent above 6 Gy [5] or 10 Gy [36],
whilst for Chernobyl survivors risk tapered above 1 Gy
[6]. Using the no-interaction dose model Q2d, RR tapers
above 400 mGy.
Unlike the thyroid, the uterus is not generally recog-
nised as radiosensitive, although [1] notes an excess of
cancers of the uterine corpus at young ages. Occupational
studies [40–42] found significant excess mortality from
uterine cancers in nuclear workers with a radiation record.
Themortality rate increased with dose, but with few cases,
mainly endometrial (corpus), ERR/Sv was not reported.
Analysing the National Registry for Radiation Workers,
Muirhead [43] found that for mortality (internally calcu-
lated SMR) amongst solid cancers, only all uterine cancers
showed trend with dose significant at the 5% level using
a two-sided test. For incidence, there was a significant
increasing trend with dose for endometrial cancer. RR was
estimated with a linear model. For incidence of uterine ca
ERR/Sv = 10.523 (0.27, 39.4)90%. Near the mean dose (24.9
mSv), this corresponds to RR|25 mSv = 1.26 (1.01, 1.99).
For incidence of corpus ca, the Health Protection Agency
[44] reported that Muirhead found ERR/Sv = 14.2 (1.06,
58.56)90%, corresponding to RR|25 mSv = 1.36 (1.03, 2.46).
For comparison, models were fitted over B+, restricted
to 16 ≤ agex < 60. For the uterus, Q2d gives
RR|25 mGy = 1.07 (0.99, 1.15). The preferred model Q3d
has RR|25 mGy, 60yrs = 0.96 (0.75, 1.23), while at age 65
RR = 1.23 (0.98 , 1.54), and at age 70, 1.29 (1.04, 1.60). For
the corpus, Q2d gives RR|25 mGy = 1.08 (0.89, 1.31). The
preferred model Q4se gives RR|25 mGy, since 30 = 5.24 (1.22,
22.55), and 4.90 (1.13, 21.24) and 4.00 (0.93, 17.14) at since
25 and 35 respectively.
Davis [16] studied solid cancer incidence in the Techa
River cohort, and found significant effects only for the
oesophagus and uterus, using a linear model without
interactions. Women constitute 57% of the cohort and age
of entry begins at 0. The mean dose was 53 mGy and 90%
of doses were below 125 mGy. For the uterus, mean age
at diagnosis was 57, and the result for ERR/100mGy =
0.21 (0.01, 0.51)95% corresponds to RR|50 mGy = 1.11
(1.01, 1.26)95%.
For comparison, models were fitted over B+. Q2d gives
RR|50mGy = 1.37 (1.09, 1.72)95%. The preferred model
Q5se gives RR|50mGy, age 60, since 15 = 1.96 (1.12, 3.42)95%,
and at since = 20, 25, 30, and 35, the corresponding
RR and 95%CI = 1.82 (1.10, 3.02), 1.67 (1.01, 2.76), 1.64
(0.99, 2.73), and 1.70 (1.02, 2.84).
Using a linear model without effect modification, Pre-
ston [1] estimated for the uterus ERR/Gy = 0.10 (-0.09,
0.33)90%, and for the corpus ERR/Gy = 0.29 (-0.14, 0.95).
However, for women with agex < 20, ERR/Gy for the
uterus = 0.37 (0.001, 0.86) and for the corpus 1.00
(0.14 , 2.40). Near the py-weighted mean dose (85.3 mGy),
with agex < 20 the model predicts for the uterus
RR|80 mGy = 1.03 (1.00, 1.07)90% and for the corpus 1.08
(1.01, 1.19).
Fitting over C+ restricted to agex < 20, for the uterus
Q2d gives RR|80 mGy = 1.79 (1.19, 2.68)90%. With the pre-
ferred model Q5se, RR|80 mGy, age 50, since 30 = 2.64 (1.17,
5.97)90%, and at since = 35, 40, 45 and 50 the corre-
sponding RR and 90%CI = 3.07 (1.41, 6.67), 4.51 (2.05,
9.94), 3.76 (1.65, 8.59), and 2.72 (1.11, 6.62). For the cor-
pus Q2d gives 1.03 (0.88, 1.21). For the preferred model
Q4ad, RR|80mGy, agex 10 = 0.88 (0.56, 1.37), whilst at agex
12, 14, 16, 18 and 20 the corresponding values are 1.13
(0.74, 1.74), 1.59 (1.05, 2.43), 2.04 (1.33, 3.11), 2.24 (1.40,
3.60), and 2.18 (0.96, 4.98), i.e. the response is higher after
puberty.
I have not used another implementation of GAM or
the fully Bayesian methods of MCMC. Confidence inter-
vals, based onWald-type CIs for the linear predictor, were
validated by simulation only for Poisson modelling of all
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solid cancers. Although the models explain nearly 60%
of the deviance for all solid cancers (in B+), the figures
for individual cancer sites are lower, given the smaller
case numbers. Minimum smoothing parameters imposed
for some sites depended on a visual judgement of the
output. The public data lacks information on other expo-
sures which may interact with radiation. The effects could
be due to confounding by some other factor linked to
distance from the hypocentres, although modelling did
control for urban, rural, or NIC location. The modelling
was not designed to test a particular hypothesis for cel-
lular mechanism, or for the higher risks for women or
Nagasaki residents.
Although increased risk with age-at-exposure (at fixed
attained age) was found for many sites, as Boice observed
[45] the flash doses all occurred in August 1945, so age-at-
exposure is confounded with birth cohort and changes in
diet, smoking habits or infection rates, may explain appar-
ent age-at-exposure (or time-since-exposure) effects. Pro-
tracted or fractionated exposures may also have different
effects.
The impact of radiation in this cohort may be affected
by blast damage. Stewart and Kneale [46] investigated
possible selection bias, as subjects were only eligible to
enter the (mortality) cohort if they survived to 1950.
Incidence data begins in 1958, with the minimum time-
since-exposure exceeding 12 years.
Wing and Richardson [47] point out that the dose esti-
mates, revised several times, also depend on “the ability
to elicit accurate information on location, position and
shielding [which] was affected not only by traumatization
of the survivors and their domestic stigmatization but by
their distrust of medical teams working under occupa-
tion forces [48].” The A-bombs annihilated Hiroshima and
Nagasaki, destroying their social fabric.
For all these reasons this cohort may not predict risk
elsewhere.
Conclusion
The Generalized Additive Model avoids potential prob-
lems in fitting a mis-specified parametric model. In fact,
the linear model is an inadequate description of rel-
ative risk for cancer incidence in female Japanese A-
bomb survivors exposed to low dose radiation. Contrary
to the interactions at high doses, for all solid can-
cers risk increases with age-at-exposure and decreases
with time-since-exposure, suggesting that low dose radi-
ation acts through progression of previously accumulated
damage.
Time-since-exposure models were generally preferred
to age-at-exposure models. Transforming dose to its
empirical cumulative distribution improved the model fit
for all solid cancers and many specific sites. Construct-
ing splines in this way improves their capacity to detect
responses at very low doses. Covariate interactions were
modelled with tensor product splines. Marginal Likeli-
hood was the preferred method of smoothing param-
eter optimisation, and confidence intervals obtained
from the Bayesian posterior covariance performed
well.
The results at 10 mGy are much higher than expected.
Whilst higher female cancer risks and the highly skewed
distribution of dose are recognised, significantly raised
Relative Risk for women exposed to low doses, not found
for all solid cancers in men, is new. Most other A-bomb
survivor studies consider much wider dose ranges.
Whilst the results may be specific to this cohort, some
studies of other cohorts with other methods give compa-
rable results, notably for thyroid cancer where estimates
are consistent with those derived here, and for the uterus.
Direct epidemiological evidence of risks from doses
around 10 mGy is a current research priority [18]. Risk
estimates derived here from low dose data are much
higher than those on which the ICRP has relied when set-
ting recommended annual dose limits [4], including the
annual occupational dose limit of 20mSv. For all solid can-
cers, almost all estimates here of Excess Relative Risk for
women at 10 mGy are 9.6 – 45.7 times the prediction by
linear extrapolation from [1].
Generalized additive models applied to the low dose
data for female Japanese A-bomb survivors show signif-
icant Relative Risks, particularly if the heavily skewed
doses are transformed to improve their distribution. Evi-
dence of elevated risk at low doses should contribute
to higher radiation risk estimates and improve radiation
protection for women.
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